3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
27
Phase 1
14
Phase 1/2
11
Phase NA
6
Phase 3
5
Phase 4
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Breast Neoplasms
27
Neoplasms
10
Carcinoma, Non-Small-Cell Lung
10
Prostatic Neoplasms
7
Multiple Myeloma
7
Lung Neoplasms
7
Melanoma
6
Stomach Neoplasms
5
Leukemia, Myeloid, Acute
5
Glioma
4
Carcinoma, Hepatocellular
4
Tuberous Sclerosis
3
Sarcoma
3
Papillomavirus Infections
3
Ovarian Neoplasms
3
Neoplasm Metastasis
3
Hematologic Neoplasms
3
Glioblastoma
3
Colorectal Neoplasms
3
Warts
2
Venous Thromboembolism
2
Thyroid Neoplasms
2
Skin Neoplasms
2
Rectal Neoplasms
2
Polycythemia Vera
2
Oligodendroglioma
2
Obesity
2
Neoplasms by Site
2
Myasthenia Gravis
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Interventions
nilotinib
1
bosutinib
1
asciminib
1
Imatinib Mesylate
1
Dasatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 4
×
Myeloproliferative Disorders
×
90 days
×
Clear all
NCT04877522
2026-05-11
Asciminib Roll-over Study
Novartis
Phase 4
Recruiting
347 enrolled